Literature DB >> 7127904

Anti-colon antibody and lymphocytophilic antibody in ulcerative colitis.

T Hibi, S Aiso, T Yoshida, M Watanabe, H Asakura, S Tsuru, M Tsuchiya.   

Abstract

The presence of anti-colon antibody in the sera from patients with ulcerative colitis was demonstrated by antibody-dependent cell-mediated cytotoxicity (ADCC) assay. In addition, the high prevalence of lymphocytophilic antibody in the sera from patients with ulcerative colitis was obtained by fluorescence activated cell sorter (FACS) analysis. This lymphocytophilic antibody was absorbed by rat colon epithelial cells. Moreover the lymphocytes from ulcerative colitis showed lower binding capacity to this antibody, but acquired higher binding capacity after 20 hr incubation at 37 degrees C in vitro. These data suggest that ADCC may have some role in the pathogenesis of ulcerative colitis.

Entities:  

Mesh：

Substances：

Year:  1982        PMID： 7127904      PMCID： PMC1536665     

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN： 0009-9104            Impact factor:   4.330


  20 in total

1.  In vitro studies of inflammatory bowel disease. Surface receptors of the mononuclear cell required to lyse allogeneic colonic epithelial cells.

Authors:  J D Stobo; T B Tomasi; K A Huizenga; R J Spencer; R G Shorter
Journal:  Gastroenterology       Date:  1976-02       Impact factor: 22.682

2.  Serum lymphocytotoxic and lymphocytophilic antibody activity in inflammatory bowel disease.

Authors:  S Korsmeyer; R G Strickland; I D Wilson; R C Williams
Journal:  Gastroenterology       Date:  1974-10       Impact factor: 22.682

3.  A rapid method for the isolation of functional thymus-derived murine lymphocytes.

Authors:  M H Julius; E Simpson; L A Herzenberg
Journal:  Eur J Immunol       Date:  1973-10       Impact factor: 5.532

4.  Negative findings in laboratory animals for a transmissible agent in Crohn's disease.

Authors:  P M Bolton; E Owen; R V Heatley; W J Williams; L E Hughes
Journal:  Lancet       Date:  1973-11-17       Impact factor: 79.321

5.  Circulating immune complexes in inflammatory bowel disease.

Authors:  D P Jewell; I C MacLennan
Journal:  Clin Exp Immunol       Date:  1973-06       Impact factor: 4.330

6.  Fluorescence activated cell sorting.

Authors:  W A Bonner; H R Hulett; R G Sweet; L A Herzenberg
Journal:  Rev Sci Instrum       Date:  1972-03       Impact factor: 1.523

7.  Lymphocyte cytotoxic antibodies in systemic lupus erythematosus.

Authors:  K K Mittal; R D Rossen; J T Sharp; M D Lidsky; W T Butler
Journal:  Nature       Date:  1970-03-28       Impact factor: 49.962

8.  Inhibition of in vitro cytotoxicity of lymphocytes from patients with ulcerative colitis and granulomatous colitis for allogeneic colonic epithelial cells using horse anti-human thymus serum.

Authors:  R G Shorter; R J Spencer; K A Huizenga; G A Hallenbeck
Journal:  Gastroenterology       Date:  1968-02       Impact factor: 22.682

9.  Immunological studies in ulcerative colitis. IV. Origin of autoantibodies.

Authors:  R Lagercrantz; S Hammarström; P Perlmann; B E Gustafsson
Journal:  J Exp Med       Date:  1968-12-01       Impact factor: 14.307

10.  Relation of GIX antigen of thymocytes to envelope glycoprotein of murine leukemia virus.

Authors:  Y Obata; H Ikeda; E Stockert; E A Boyse
Journal:  J Exp Med       Date:  1975-01-01       Impact factor: 14.307
View more
  14 in total

1.  Generation of MHC class I-restricted cytotoxic T cell lines and clones against colonic epithelial cells from ulcerative colitis.

Authors:  Y Yonamine; M Watanabe; F Kinjo; T Hibi
Journal:  J Clin Immunol       Date:  1999-01       Impact factor: 8.317

2.  HLA class-I-restricted and colon-specific cytotoxic T cells from lamina propria lymphocytes of patients with ulcerative colitis.

Authors:  T Sunagawa; Y Yonamine; F Kinjo; M Watanabe; T Hibi; A Saito
Journal:  J Clin Immunol       Date:  2001-11       Impact factor: 8.317

3.  In vitro anticolon antibody production by mucosal or peripheral blood lymphocytes from patients with ulcerative colitis.

Authors:  T Hibi; M Ohara; K Toda; A Hara; H Ogata; Y Iwao; N Watanabe; M Watanabe; Y Hamada; K Kobayashi
Journal:  Gut       Date:  1990-12       Impact factor: 23.059

Review 4.  The immunologic basis of inflammatory bowel disease.

Authors:  W Strober; S P James
Journal:  J Clin Immunol       Date:  1986-11       Impact factor: 8.317

5.  Enzyme linked immunosorbent assay (ELISA) and immunoprecipitation studies on anti-goblet cell antibody using a mucin producing cell line in patients with inflammatory bowel disease.

Authors:  T Hibi; M Ohara; K Kobayashi; W R Brown; K Toda; H Takaishi; Y Hosoda; A Hayashi; Y Iwao; M Watanabe
Journal:  Gut       Date:  1994-02       Impact factor: 23.059

6.  Circulating antibodies to the surface antigens on colon epithelial cells in ulcerative colitis.

Authors:  T Hibi; S Aiso; M Ishikawa; M Watanabe; T Yoshida; K Kobayashi; H Asakura; S Tsuru; M Tsuchiya
Journal:  Clin Exp Immunol       Date:  1983-10       Impact factor: 4.330

7.  Immunological abnormalities involving the thymus in ulcerative colitis and therapeutic effects of thymectomy.

Authors:  M Tsuchiya
Journal:  Gastroenterol Jpn       Date:  1984-06

8.  Ulcerative colitis with arthritis and vasculitis.

Authors:  J C Speiser; T L Moore; J Zuckner
Journal:  Clin Rheumatol       Date:  1985-09       Impact factor: 2.980

9.  Interleukin 2 and interferon-gamma augment anticolon antibody dependent cellular cytotoxicity in ulcerative colitis.

Authors:  T Hibi; M Ohara; M Watanabe; T Kanai; H Takaishi; A Hayashi; Y Hosoda; H Ogata; Y Iwao; S Aiso
Journal:  Gut       Date:  1993-06       Impact factor: 23.059

10.  Ulcerative colitis complicated by gastroduodenal lesions.

Authors:  M Sasaki; K Okada; S Koyama; U Yoshioka; H Inoue; Y Fujiyama; T Bamba
Journal:  J Gastroenterol       Date:  1996-08       Impact factor: 7.527
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.